Form: SC 13G/A

Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions

January 21, 2022

Documents

 

Exhibit A

Joint Filing Agreement

 

The undersigned hereby agree that this Statement on Schedule 13G/A with respect to the beneficial ownership of shares of Common Stock of Cellectar Biosciences, Inc. is filed jointly, on behalf of each of them. 

     
  Rosalind Advisors, Inc.
  By: /s/ Steven Salamon
  Name: Steven Salamon
  Title: President
     
  Rosalind Master Fund L.P.
  By:  /s/ Mike McDonald
  Name: Mike McDonald
  Title: Director, Rosalind (Cayman) Ltd.
(as General Partner to Rosalind Master Fund)
   
  By: /s/ Steven Salamon
  Name: Steven Salamon